New classifications have eliminated MLD criteria to define AML myelodysplasia-related (AML-MR) but recognize mutations in ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2 as a novel criteria. This evidence concerns the gene EZH2 and acute myeloid leukemia.